46 results on '"Andersson, Emma I."'
Search Results
2. Supplementary Tables S1-S7 from Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
3. Supplementary Figures S1-S16 from Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
4. Data from Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
5. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
6. Additional file 1 of CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
7. STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(-) ALCL
8. CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
9. Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
10. STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK− ALCL
11. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
12. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia
13. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
14. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
15. Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions
16. Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia
17. A guilt-by-association mutation network in LGL leukemia
18. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
19. Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia
20. Novel Mutations in NOTCH and Altered Wnt/beta-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia
21. Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia
22. Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia
23. Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies
24. Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling
25. Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells
26. Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling
27. Abstract 606: Novel somatic mutations in the DNA-binding and coiled-coil domain of the STAT3 gene in LGL-leukemia
28. A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses
29. Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies
30. Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling
31. Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients
32. Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing
33. Abstract 3164: Somatic mutation analysis pipeline for exome-sequencing data identifies oncogenic STAT3 mutations in T-LGL leukemia.
34. Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia
35. Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia
36. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
37. High incidence of activating STAT5Bmutations in CD4-positive T-cell large granular lymphocyte leukemia
38. Novel Mutations in NOTCHand Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia
39. Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex VivoDrug Testing and Genetic Profiling
40. Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex VivoDrug Testing and Genetic Profiling
41. A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex VivoDrug Responses
42. Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex VivoDrug Testing
43. Multiple STAT3Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients
44. STAT3 Mutation Is Associated with STAT3 Activation in CD30 + ALK - ALCL.
45. Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8 + TCR-Vβ + expansions.
46. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.